List of Excipients in Branded Drug XOPENEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	XOPENEX	levalbuterol hydrochloride	17478-171	HYDROCHLORIC ACID
Akorn	XOPENEX	levalbuterol hydrochloride	17478-171	NITROGEN
Akorn	XOPENEX	levalbuterol hydrochloride	17478-171	SODIUM CHLORIDE
Akorn	XOPENEX	levalbuterol hydrochloride	17478-171	WATER

XOPENEX Excipient Strategy and Commercial Opportunities for Levalbuterol Inhalation Products

Last updated: August 21, 2026

XOPENEX is the brand name for levalbuterol, the R-enantiomer of albuterol used for acute treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. Its commercial opportunity is concentrated in inhalation delivery, where excipient selection affects dose consistency, microbial control, device compatibility, patient tolerability, and regulatory substitutability.

The strongest opportunities are preservative-free nebulizer solutions, low-impact hydrofluoroalkane pressurized metered-dose inhalers, unit-dose packaging, and differentiated generic products for pediatric and home-use settings. The principal commercial risks are established generic competition, limited clinical differentiation between levalbuterol and racemic albuterol, and the need to demonstrate pharmaceutical equivalence through device and aerodynamic-performance testing.

What formulations does XOPENEX contain?

XOPENEX has been marketed in nebulizer and metered-dose inhaler formulations.

Product	Active ingredient	Typical strength	Dosage form	Key excipients or formulation components
XOPENEX Inhalation Solution	Levalbuterol hydrochloride	0.31, 0.63, 1.25 mg per 3 mL	Nebulizer solution	Sodium chloride, water for injection; preservative-free unit-dose presentation
XOPENEX Concentrate	Levalbuterol hydrochloride	1.25 mg per 0.5 mL	Concentrated nebulizer solution	Requires dilution before nebulization; formulation is designed for lower fill volume
XOPENEX HFA	Levalbuterol tartrate	45 mcg per actuation	Pressurized metered-dose inhaler	HFA-134a propellant, ethanol, oleic acid

The inhalation solution uses an aqueous saline vehicle. The 3-mL unit-dose products are intended for direct use in compatible nebulizers. The concentrate requires dilution with sterile normal saline before administration, creating a separate handling and compliance profile. XOPENEX HFA uses a hydrofluoroalkane propellant system rather than a chlorofluorocarbon propellant system. FDA labeling identifies ethanol and oleic acid as formulation components for the HFA product (FDA, XOPENEX HFA Prescribing Information; DailyMed, XOPENEX).

How does levalbuterol differ from racemic albuterol?

Levalbuterol is the R-enantiomer of albuterol. Racemic albuterol contains both R- and S-enantiomers. The commercial rationale for levalbuterol has historically centered on achieving bronchodilation with a lower nominal dose and potentially reducing adverse effects associated with the S-enantiomer.

The differentiation is limited by several factors:

• Generic albuterol is widely available at low cost.
• Clinical outcomes can overlap at commonly used doses.
• Payers frequently evaluate levalbuterol as a higher-cost alternative to racemic albuterol.
• Excipient or device improvements must be meaningful enough to offset the active-ingredient price disadvantage.

What excipients protect XOPENEX inhalation performance?

Nebulizer solution excipients

The principal excipient strategy for XOPENEX inhalation solution is deliberately simple:

1. Sodium chloride provides isotonicity.
2. Water for injection is the aqueous vehicle.
3. Unit-dose sterile packaging limits the need for antimicrobial preservatives.

This formulation approach reduces risks associated with preservative exposure, especially in pediatric, chronic-use, and high-frequency nebulizer populations. It also simplifies the target product profile for generic development.

The critical quality attributes are not limited to assay and pH. A sponsor must control:

• Delivered dose uniformity.
• Particle-size distribution after nebulization.
• Residual volume.
• Osmolality.
• pH.
• Sterility and container-closure integrity.
• Stability under refrigerated and room-temperature conditions.
• Compatibility with the intended nebulizer platform.

The absence of a preservative does not eliminate manufacturing complexity. Sterile filling, low-bioburden processing, container-closure validation, and stability control become central manufacturing barriers.

HFA inhaler excipients

XOPENEX HFA uses a propellant-based formulation with ethanol and oleic acid. Each component has a defined technical role:

• HFA-134a is the propellant.
• Ethanol acts as a cosolvent and can influence solubility, plume characteristics, and vapor pressure.
• Oleic acid functions as a surfactant or formulation aid and can influence suspension behavior and valve performance.

A reformulation using different ethanol concentration, alternative surfactant levels, or a different actuator may materially alter:

• Emitted dose.
• Fine-particle dose.
• Spray pattern.
• Plume geometry.
• Mouth and throat deposition.
• Canister-valve interaction.
• Product stability.
• Priming and repriming performance.

For this reason, an HFA generic cannot rely on chemical sameness alone. The device, formulation, actuator, and manufacturing process must be evaluated as an integrated drug-delivery system.

What excipient strategies create commercial opportunities for XOPENEX products?

1. Preservative-free nebulizer solutions

Preservative-free unit-dose levalbuterol is the most straightforward opportunity. The strategy targets patients who require repeated nebulization and may be sensitive to preservatives used in multidose inhalation products.

Commercial advantages include:

• Simple formulation composition.
• Lower excipient-related toxicology burden.
• Strong pediatric and home-care positioning.
• Compatibility with standard jet nebulizer use.
• Potential for contract manufacturing using established sterile-fill infrastructure.

The main limitation is that a basic saline formulation is difficult to differentiate through composition alone. Commercial value must come from supply reliability, packaging, price, reduced waste, or device compatibility.

2. Low-fill-volume concentrates

The 0.5-mL concentrate format can reduce liquid fill volume and packaging mass. It may be attractive for institutional, ambulance, emergency-department, and home-care use where storage space matters.

The disadvantage is administration complexity. The product must be diluted before nebulization, creating risks of preparation error and incomplete dose delivery. A commercial program should therefore evaluate:

• Premeasured dilution systems.
• Integrated saline ampoules.
• Packaging with clear dilution instructions.
• Compatibility with closed-system nebulizers.
• Unit-dose designs that reduce transfer steps.

A concentrate with improved handling can create more defensible value than a formulation change involving only buffer or tonicity.

3. Excipient and container systems for mesh nebulizers

Vibrating-mesh nebulizers are increasingly relevant to portable and home-use delivery. Their performance can be affected by viscosity, surface tension, crystallization, particulate matter, and residual volume.

Potential formulation strategies include controlled osmolality and surface tension without introducing unnecessary preservatives or complex buffers. The product must be tested in the specific mesh device because nebulization performance is device-dependent.

The commercial opportunity is strongest where a supplier can offer a validated drug-device combination rather than a commodity vial. This approach may support proprietary device positioning, although it increases combination-product development and regulatory requirements.

4. HFA reformulation and actuator optimization

The HFA product offers a platform for differentiated generic or authorized-generic development. Potential areas include:

• Alternative actuator geometry.
• Improved dose-counter integration.
• Reduced throat deposition.
• Lower residual volume.
• Better suspension homogeneity.
• More robust priming and repriming behavior.
• Lower ethanol concentration, if performance can be maintained.
• Ergonomic designs for pediatric and elderly patients.

The technical risk is high. Small changes in formulation composition can produce large changes in aerosol performance. A sponsor must align the formulation with the reference inhaler across delivered dose, aerodynamic particle-size distribution, spray characteristics, and stability.

What FDA pathway applies to generic XOPENEX?

The primary pathway for small-molecule generic levalbuterol products is an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Product type	Likely regulatory pathway	Core development issue
Levalbuterol inhalation solution	ANDA	Pharmaceutical equivalence, sterility, nebulizer performance
Concentrated inhalation solution	ANDA or potentially a 505(b)(2) strategy depending on product differences	Dilution instructions, device compatibility, comparative performance
Levalbuterol HFA inhaler	ANDA or 505(b)(2), depending on formulation and device differences	In vitro equivalence, aerodynamic performance, device comparability
Novel drug-device combination	505(b)(2) or NDA strategy	Clinical or human-factor evidence may be required
Reformulated preservative-free product	ANDA if equivalence remains within the reference-product framework; otherwise 505(b)(2)	Excipient and device differences

FDA’s product-specific guidance and current recommendations for orally inhaled products control the evidence package. Inhalation products generally require more extensive in vitro characterization than conventional oral dosage forms. The submission must address dose delivery through the complete container-closure and device system, not only the bulk formulation.

What is the Orange Book and exclusivity status of XOPENEX?

XOPENEX products are small-molecule inhalation products rather than biologics. Biosimilar competition is therefore not applicable. Competition occurs through generic drug applications and, for differentiated delivery systems, possible 505(b)(2) applications.

The relevant reference-product families include:

Brand product	FDA application family	Active ingredient
XOPENEX Inhalation Solution	NDA 020837 family	Levalbuterol hydrochloride
XOPENEX HFA	NDA 021457 family	Levalbuterol tartrate

The original five-year new chemical entity exclusivity periods and any pediatric exclusivity associated with the original approvals are historical and have expired. Current market access depends primarily on patent status, regulatory exclusivity attached to later products, ANDA approval timing, and commercial execution.

Orange Book analysis should distinguish among:

• Active listed patents, if any.
• Expired formulation or method-of-use patents.
• Drug-substance patents.
• Device-related protection that may not be listed in the same manner as drug-product patents.
• Patent certifications submitted with ANDAs.
• Exclusivity attached to a later-approved formulation rather than the original brand.

A definitive launch assessment requires the current FDA Orange Book entries and litigation docket for each application family. Patent expiration should not be inferred from the original approval date alone.

What Paragraph IV risks affect XOPENEX generics?

Paragraph IV risk is product-specific. The main risk categories are:

1. Formulation patents covering the HFA system, surfactant, cosolvent, or suspension characteristics.
2. Device patents covering the actuator, valve, dose counter, or inhaler assembly.
3. Method-of-use patents covering dosing in particular age groups or disease settings.
4. Manufacturing patents covering sterile filling, suspension processing, or canister preparation.
5. Patent listings that are challenged even when the commercial value of the patent is limited.

For nebulizer solutions, the formulation is comparatively simple, so patent risk may be lower than for HFA inhalers. The larger barriers are sterile manufacturing and demonstrating performance across nebulizer types.

For HFA products, the patent landscape is usually more complex because the drug product includes formulation and device attributes. An ANDA applicant may use a Paragraph IV certification to pursue an early launch, but the commercial decision depends on expected litigation cost, 30-month-stay exposure, first-filer status, and the probability that the asserted patents survive invalidity and noninfringement challenges.

How strong is the XOPENEX patent estate?

The estate is structurally weaker for a basic preservative-free nebulizer solution than for a proprietary HFA inhaler system.

Patent category	Relative strategic value	Main vulnerability
Simple saline nebulizer formulation	Low to moderate	Limited compositional distinction
Concentrate and dilution format	Moderate	Design-around through fill volume or instructions
HFA formulation	Moderate to high	Narrow claim scope and prior-art exposure
Actuator or valve design	Moderate to high	Noninfringement through alternative device architecture
Dose-counter integration	Moderate	Separate device claims and regulatory complexity
Method of use	Variable	Indication overlap and patent-eligibility challenges
Manufacturing process	Moderate	Difficult to detect infringement and often design-aroundable

The most defensible protection generally combines formulation, device, manufacturing, and use claims. A single narrow excipient claim is unlikely to sustain durable commercial exclusivity against a capable inhalation-product developer.

Which companies are positioned to challenge XOPENEX?

Competition is likely to come from three groups:

• Established generic inhalation manufacturers with sterile-fill and device capabilities.
• Specialty respiratory companies with nebulizer platforms.
• Contract development and manufacturing organizations offering integrated inhalation services.

The strongest competitors are those that can manufacture both the drug product and the delivery system. A company with only liquid sterile-fill capacity may compete effectively in nebulizer solutions but face greater barriers in HFA products.

Direct competition also comes from racemic albuterol products, including generic albuterol sulfate inhalation solution and albuterol HFA inhalers. These products can constrain levalbuterol pricing even when they are not therapeutically identical at the molecular level.

What licensing and partnership opportunities exist?

Commercial partnership opportunities are concentrated in four areas:

Inhaler devices

A levalbuterol HFA sponsor can license an established actuator, valve, or dose-counter platform. This may reduce development time but can create royalty obligations and supply dependence.

Sterile unit-dose manufacturing

A sponsor without aseptic filling capacity can contract with a facility experienced in inhalation solutions. The key diligence points are container-closure capability, capacity reservation, inspection history, and validated fill accuracy.

Nebulizer combinations

A drug-device partnership can differentiate a levalbuterol product through portability, reduced residual volume, or improved administration workflow. The arrangement must allocate regulatory responsibilities for the drug, device, labeling, and postmarket reporting.

Authorized generics

An authorized-generic arrangement can provide a lower-cost commercial channel while preserving brand participation. Its value depends on whether the brand product remains commercially supported and whether the arrangement creates channel conflict with independent generic entrants.

What revenue exposure and launch scenarios apply to XOPENEX?

Standalone XOPENEX revenue is difficult to assess because respiratory portfolios may be reported in aggregate and because generic erosion changes the commercial base over time. The principal revenue drivers are product format and payer positioning.

Launch scenario	Commercial profile	Primary risk
Commodity nebulizer solution	Fastest development and broadest pharmacy access	Price compression
Premium preservative-free unit dose	Better pediatric and chronic-use positioning	Limited willingness to pay
Concentrate with improved handling	Potential institutional efficiency	Dilution burden
HFA generic	Higher value per unit and portable use	Device and equivalence complexity
Integrated nebulizer product	Differentiated user experience	Combination-product cost
Authorized generic	Rapid market access	Lower margin and channel overlap

A generic launch may produce rapid volume capture but severe price erosion. A differentiated product can support higher pricing only if it solves a measurable administration or adherence problem. Excipient changes alone rarely create strong market exclusivity unless paired with device, packaging, or regulatory differentiation.

What manufacturing and intellectual-property barriers matter most?

The principal barriers are operational rather than purely chemical.

For nebulizer solutions, the critical barriers are:

• Aseptic processing.
• Low extractables and leachables from plastic unit-dose containers.
• Sterility assurance.
• Fill-volume control.
• Stability under heat and light.
• Compatibility with multiple nebulizer systems.

For HFA inhalers, the barriers include:

• Canister and valve sourcing.
• Propellant and ethanol control.
• Suspension uniformity.
• Dose-counter reliability.
• Actuator reproducibility.
• Aerosol particle-size testing.
• Device assembly and performance over product life.

The most attractive development strategy is usually a staged portfolio: begin with preservative-free unit-dose solution, then evaluate a concentrate or device-integrated product, and pursue HFA only if the sponsor has adequate inhalation-device capability.

Key Takeaways

• XOPENEX is levalbuterol, a small-molecule bronchodilator with no biosimilar pathway.
• The simplest commercial opportunity is preservative-free levalbuterol nebulizer solution.
• HFA products offer greater differentiation but carry higher device, formulation, and equivalence risk.
• Sodium chloride and water for injection provide a low-complexity vehicle for nebulizer products.
• HFA-134a, ethanol, and oleic acid require tight control because they affect aerosol performance.
• Generic competition is the principal threat to pricing.
• Product-device integration, packaging, and handling improvements offer stronger differentiation than minor excipient substitutions.
• Sterile manufacturing and inhalation-performance testing are major barriers to entry.
• Orange Book and litigation analysis must be performed by product and current listing, not by brand name alone.
• Commercial success depends on solving a delivery or workflow problem that generic albuterol does not solve at lower cost.

FAQs About XOPENEX Excipient and Commercial Strategy

Is XOPENEX inhalation solution preservative-free?

The standard unit-dose XOPENEX inhalation solution is labeled as preservative-free. Its formulation uses levalbuterol hydrochloride in an aqueous sodium chloride vehicle.

Can a generic XOPENEX inhalation solution use different excipients?

A generic product may use different excipients only within the applicable FDA equivalence framework. Changes that affect safety, stability, delivered dose, or nebulization performance can trigger additional regulatory requirements.

Is XOPENEX HFA a suspension or solution inhaler?

The formulation and physical presentation must be evaluated through the approved product labeling and product-specific guidance. The HFA system contains propellant, ethanol, and oleic acid, and its performance depends on the formulation-device combination.

Does levalbuterol have stronger commercial protection than albuterol?

Levalbuterol may have product-specific formulation or device protection, but it competes against widely available generic albuterol. Its commercial protection is therefore more dependent on patents, delivery technology, and contracting than on the active ingredient alone.

What is the best excipient opportunity for a new levalbuterol product?

The most practical opportunity is a preservative-free, unit-dose nebulizer solution with validated performance in portable or vibrating-mesh nebulizers. A differentiated packaging and device workflow can provide more commercial value than a minor change to saline concentration or buffer composition.

References

1. U.S. Food and Drug Administration. (n.d.). XOPENEX HFA prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). XOPENEX inhalation solution prescribing information. FDA.
3. National Library of Medicine. (n.d.). DailyMed: XOPENEX and levalbuterol product labeling. U.S. National Library of Medicine.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
5. U.S. Food and Drug Administration. (n.d.). ANDAs for certain highly purified synthetic peptides and orally inhaled drug products: Product-specific guidance and regulatory guidance. FDA.